Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9419870 | 0.96 | SNCA (0.53) | SNCAALDH1A1TSHRKIF11PPARG | |
| Bromide SCHEMBL16393752 | 0.86 | SNCA (0.53) | SNCAALDH1A1TSHRPPARGPPARA | |
| Bromide SCHEMBL39844 | 0.84 | SNCA (0.73) | SNCAALDH1A1TSHRTAAR1HIF1A | |
| Bromide SCHEMBL9538904 | 0.84 | SNCA (0.46) | SNCA | |
| Bromide SCHEMBL8745295 | 0.82 | TAAR1 (0.47) | ALDH1A1TSHRKIF11TAAR1ACP3 | |
| Bromide SCHEMBL6885441 | 0.81 | SNCA (0.56) | SNCAALDH1A1TSHRHIF1ANPC1 | |
| Bromide SCHEMBL2647553 | 0.81 | HTR2A (0.54) | SNCATSHRPPARGPPARATAAR1 | |
| Bromide SCHEMBL6178273 | 0.80 | KIF11 (0.42) | SNCAALDH1A1TSHRKIF11PPARG | |
| Iodide SCHEMBL16398702 | 0.80 | TACR1 (0.45) | SNCA | |
| Iodide SCHEMBL9321342 | 0.80 | SNCA (0.69) | SNCAALDH1A1TSHRTAAR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | claimed |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | BRIDGENE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024091511-A1 | HETEROCYCLIC TEAD INHIBITORS | LIGHT HORSE THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-0456149-A1 | 9-Substituted compounds of 3 alpha, 11 alpha-Epoxy-3,4,5, 5a alpha,6,7,8,8a,9,11,11a-undecahydro-3 beta, 6 alpha, 9-trimethylfurano[3,4-j][1,2]-benzodioxepin, processes for their preparation and their use as antiprotozoal and antiviral agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-13 | — | — | EP | disclosed |
| US-5032607-A | Enzyme inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-07-16 | — | — | US | disclosed |
| US-4977184-A | Bicyclic peroxides compositions for and treatment of malaria therewith | HOFFMANN-LA ROCHE INC. (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0220810-B1 | INSECTICIDAL ETHERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-02 | — | — | EP | disclosed |
| US-4866086-A | PHENYLTRIAZOLYL OLEFINIC AROMATASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-09-12 | — | — | US | disclosed |
| EP-0311955-A2 | Bicyclic peroxide | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-19 | — | — | EP | disclosed |
| EP-0299683-A2 | Heterocyclic olefinic compounds and their use as aromatase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-01-18 | — | — | EP | disclosed |
| US-4788348-A | HYDROXY AROMATIC ETHERS AS CHEMICAL INTERMEDIATES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-11-29 | — | — | US | disclosed |
| US-4705900-A | Insecticidal alkenes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-11-10 | — | — | US | disclosed |
| EP-0220810-A1 | Insecticidal ethers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | SNCA 3520/4885ALDH1A1 1338/4885TSHR 1083/4885 |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | YAP1, TEAD1, TEAD2 | SNCA 660/4885ALDH1A1 3155/4885TSHR 1551/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | SNCA 3399/4885ALDH1A1 525/4885TSHR 1624/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | SNCA 3399/4885ALDH1A1 525/4885TSHR 1624/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | SNCA 1159/4885ALDH1A1 472/4885TSHR 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.